Cepheid Q2 results should beat expectations, says Wedbush Wedbush thinks the high number of Cepheid's Infinity placements in 4Q13 and Q1 could boost the company's Q2 results. The firm keeps a $58 price target and Outperform rating on the shares.
Cepheid receives FDA emergency use authorization for Xpert Ebola diagnostic test Cepheid announced it has received Emergency Use Authorization from the FDA for Xpert Ebola, a molecular diagnostic test for Ebola Zaire Virus that delivers results in less than two hours. The test runs on the Cepheid GeneXpert Systems. Xpert Ebola has been authorized by FDA under an Emergency Use Authorization for use by CLIA moderate and high complexity laboratories or similarly qualified non-U.S. laboratories. The test will begin shipping in April. Cepheid's Xpert Ebola has not been FDA cleared or approved, but will remain available in the U.S. as an EUA product as long as the declared emergency remains in effect or it ceases to be authorized by FDA.